A preclinical study demonstrated that knocking out two prostaglandin E2 (PGE2) receptors in CAR‑T cells markedly improves their activity against solid tumours. The engineered cells showed enhanced persistence, cytokine production, and tumour infiltration in murine models. Authors position the dual‑receptor strategy as a way to blunt an immunosuppressive axis in the tumour microenvironment; the approach may be paired with existing CAR constructs to tackle the longstanding challenge of CAR‑T efficacy outside hematologic malignancies.